Chiesi Global Rare Diseases Announces FDA Approval of Ferriprox (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease
May 1, 2021
Approval is based on demonstrated reduction in liver iron concentration
Expanded indications for patients with sickle cell disease or other anemias, as well as thalassemia -
BOSTON, May 1, 2021 /PRNewswire/ -- Chiesi Global Rare...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Iron | Liver | Rare Diseases | Sickle Cell Anemia | Urology & Nephrology